Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma × E-3810 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Solid Tumors 1 Ovarian Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Genital Neoplasms, Female 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Carcinoma 1 Advanced Solid Tumors 1 Acrocephalosyndactylia 1

Interventions

Cisplatin 46 Carboplatin 43 pembrolizumab 39 Paclitaxel 38 Gemcitabine 27 Radiotherapy 19 Pemetrexed 19 Magnetic Resonance Spectroscopy 18 Radiotherapy, Intensity-Modulated 17 Docetaxel 17 Specimen Handling 15 Nivolumab 15 Cetuximab 15 Cyclophosphamide 14 durvalumab 13 Fluorouracil 13 130-nm albumin-bound paclitaxel 10 Platinum 9 Bevacizumab 9 osimertinib 8 Sunitinib 8 Sorafenib 8 Radiation 8 Oxaliplatin 8 Irinotecan 8 Everolimus 8 Capecitabine 8 1,2-diaminocyclohexaneplatinum II citrate 8 Ipilimumab 7 Drug Therapy 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04151563 2023-12-19

CheckMate 79X

Bristol-Myers Squibb

Phase 1/2 Withdrawn

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡